200 studies found for:    Open Studies | "Protozoan Infections"
Show Display Options
Rank Status Study
21 Recruiting Diagnosis and Treatment of Leishmanial Infections
Condition: Leishmaniasis
22 Unknown  A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso
Condition: Malaria
Interventions: Biological: MSP 3 Long Synthetic Peptide;   Biological: Hepatitis B vaccine;   Biological: Hepatitis B control vaccince
23 Unknown  Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana
Conditions: Malaria;   Schistosomiasis;   Helminthiasis;   Anemia;   Change in Sustained Attention
Interventions: Drug: Artemether-lumefantrine combination plus albendazole;   Drug: Artemether-lumefantrine plus Praziquantel plus Albendazole;   Drug: Albendazole plus Praziquantel
24 Unknown  Trial for Malaria Vaccine Candidate, PfPEBS (P. Falciparum Pre-Erythrocytic and Blood Stage)
Condition: Malaria
Interventions: Biological: Lyophilised PEBS synthetic protein (PfPEBS);   Other: Rehydragel™ HPA
25 Recruiting Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge
Conditions: Plasmodium Falciparum Malaria;   Malaria
Interventions: Biological: PfSPZ Challenge;   Drug: clindamycin
26 Not yet recruiting Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO
Conditions: Plasmodium Falciparum;   Malaria, Falciparum
Interventions: Drug: artemisinin/naphthoquine;   Drug: dihydroartemisinin/piperaquine phosphate
27 Not yet recruiting Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax
Condition: Malaria
Interventions: Biological: Vaccine PvCS N+C+R;   Biological: Vaccine PvCS N+C;   Biological: SSN Montanide ISA-51
28 Recruiting Incidence of Vivax Along the Thai Burma Border
Condition: Vivax Malaria
Intervention: Drug: Primaquine
29 Recruiting Congenital Transmission of Lineages I and II of Trypanosoma Cruzi
Condition: Chagas Disease
30 Recruiting Auranofin PK Following Oral Dose Administration
Condition: Amoebiasis
Intervention: Drug: Auranofin
31 Recruiting Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy
Condition: Malaria
Interventions: Drug: dihydroartemisinin-piperaquine;   Drug: Artesunate-mefloquine;   Drug: arthemeter-lumefantrin
32 Unknown  Malarial Immunity in Pregnant Cameroonian Women
Condition: Plasmodium Falciparum Malaria
33 Recruiting WR 279,396 for the Treatment of Cutaneous Leishmaniasis
Condition: Cutaneous Leishmaniasis
Intervention: Drug: WR 279,396
34 Recruiting Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib
Condition: Malaria
Intervention: Biological: P27A vaccine candidate
35 Recruiting Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis
Condition: Malaria
Interventions: Biological: CPS-immunization;   Biological: Controlled Human Malaria Infection;   Drug: chloroquine;   Drug: atovaquone/proguanil
36 Recruiting Controlled Human Malaria Infection After Bites From Mosquitoes Infected With Two Novel P. Falciparum Strains
Condition: Malaria
Interventions: Other: NF135 n=5;   Other: NF135 n=2;   Other: NF135 n=1;   Other: NF166 n=5;   Other: NF166 n=2;   Other: NF166 n=1
37 Recruiting Phase IIb Study to Investigate the Efficacy of OZ439 & Piperaquine Phosphate Co-administered to Adults & Children With Uncomplicated Plasmodium Falciparum.
Condition: Uncomplicated Plasmodium Falciparum Malaria
Interventions: Drug: A) OZ439 800mg: PQP  1440mg;   Drug: B) OZ439 800mg: PQP  960mg;   Drug: C) OZ439 800mg: PQP  640mg
38 Recruiting MicroRNAs as Biomarkers in Patients With Chagas Disease
Condition: Chagas Disease
39 Unknown  Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment
Condition: Severe Malaria
Intervention: Drug: intravenous artesunate
40 Recruiting Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia
Condition: Cutaneous Leishmaniasis
Intervention: Drug: Topical Amphotericin B at 3%

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years